NASDAQ:POAI - Nasdaq - US74039M3097 - Common Stock - Currency: USD
1.25
-0.02 (-1.57%)
The current stock price of POAI is 1.25 USD. In the past month the price decreased by -17.22%. In the past year, price decreased by -57.04%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.93 | 234.29B | ||
ISRG | INTUITIVE SURGICAL INC | 73.47 | 192.09B | ||
BSX | BOSTON SCIENTIFIC CORP | 40.16 | 148.56B | ||
SYK | STRYKER CORP | 31.36 | 145.74B | ||
MDT | MEDTRONIC PLC | 17.44 | 119.42B | ||
BDX | BECTON DICKINSON AND CO | 16.2 | 64.70B | ||
EW | EDWARDS LIFESCIENCES CORP | 27.4 | 42.35B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 19.02 | 39.02B | ||
IDXX | IDEXX LABORATORIES INC | 38.14 | 35.13B | ||
RMD | RESMED INC | 25.46 | 33.05B | ||
DXCM | DEXCOM INC | 48.19 | 31.06B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 18.17 | 25.44B |
Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 34 full-time employees. The company went IPO on 2009-12-18. The firm operates through three segments: Pittsburgh, Birmingham, and Eagan. Pittsburgh segment provides services, which include the application of artificial intelligence (AI) using its proprietary biobank of 150,000 plus tumor samples. Pittsburgh segment also develops tumor-specific in vitro models for oncology drug discovery and research. Birmingham segment focuses on contract services and research for biopharmaceutical company clients and academic collaborators, focused on solubility improvements, stability studies, and protein production. Specifically, Birmingham provides optimized formulations for vaccines, antibodies, and other protein therapeutics. Eagan segment produces the STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal.
PREDICTIVE ONCOLOGY INC
91 43Rd Street, Suite 110
Pittsburgh PENNSYLVANIA 55121 US
CEO: Carl Schwartz
Employees: 35
Company Website: https://predictive-oncology.com/
Investor Relations: http://investors.predictive-oncology.com
Phone: 14124321500
The current stock price of POAI is 1.25 USD. The price decreased by -1.57% in the last trading session.
The exchange symbol of PREDICTIVE ONCOLOGY INC is POAI and it is listed on the Nasdaq exchange.
POAI stock is listed on the Nasdaq exchange.
6 analysts have analysed POAI and the average price target is 3.06 USD. This implies a price increase of 144.8% is expected in the next year compared to the current price of 1.25. Check the PREDICTIVE ONCOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
PREDICTIVE ONCOLOGY INC (POAI) has a market capitalization of 8.34M USD. This makes POAI a Nano Cap stock.
PREDICTIVE ONCOLOGY INC (POAI) currently has 35 employees.
PREDICTIVE ONCOLOGY INC (POAI) has a support level at 1.24 and a resistance level at 1.42. Check the full technical report for a detailed analysis of POAI support and resistance levels.
The Revenue of PREDICTIVE ONCOLOGY INC (POAI) is expected to decline by -90.58% in the next year. Check the estimates tab for more information on the POAI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
POAI does not pay a dividend.
PREDICTIVE ONCOLOGY INC (POAI) will report earnings on 2025-03-26.
PREDICTIVE ONCOLOGY INC (POAI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.06).
The outstanding short interest for PREDICTIVE ONCOLOGY INC (POAI) is 7.06% of its float. Check the ownership tab for more information on the POAI short interest.
ChartMill assigns a technical rating of 4 / 10 to POAI. When comparing the yearly performance of all stocks, POAI turns out to be only a medium performer in the overall market: it outperformed 51.47% of all stocks.
ChartMill assigns a fundamental rating of 1 / 10 to POAI. POAI may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months POAI reported a non-GAAP Earnings per Share(EPS) of -3.06. The EPS increased by 34% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -186.31% | ||
ROE | -710.23% | ||
Debt/Equity | 0.1 |
ChartMill assigns a Buy % Consensus number of 43% to POAI. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of -1633.33% and a revenue growth -90.58% for POAI